The PROTAC PARP1 degrader is primarily used in targeted protein degradation, a cutting-edge approach in drug development. It is designed to selectively degrade PARP1, a protein involved in DNA repair, by recruiting an E3 ubiquitin ligase to tag PARP1 for proteasomal destruction. This application is particularly significant in cancer research, as PARP1 is often overactive in cancer cells, contributing to their survival and resistance to treatments. By degrading PARP1, this compound can sensitize cancer cells to DNA-damaging therapies, such as chemotherapy or radiation, potentially improving treatment outcomes. Additionally, it serves as a valuable tool in studying PARP1's biological functions and exploring its role in diseases beyond cancer, such as neurodegenerative disorders. Its ability to selectively target and degrade PARP1 offers a more precise and potentially less toxic alternative to traditional PARP inhibitors.